



11-618-C100

Monoclonal Antibody to CD229 Purified Antibody (0.1 mg)

Clone: HLy9.25

Isotype: Mouse IgG1

Specificity: The mouse monoclonal antibody HLy9.25 (also known as HLy9.1.25) recognizes

CD229 / Ly9, a 100-120 kDa cell surface glycoprotein expressed on T and B cells.

Regulatory Status: RUO

Immunogen: CD299-transfected 300.19 pre-B cell line

Species Reactivity: Human

Application: Flow Cytometry

Recommended dilution:6 µg/ml

Positive control:peripheral blood lymphocytes

Immunoprecipitation Western Blotting Immunocytochemistry Functional Application Regulation of activation

Purity: > 95% (by SDS-PAGE)

Purification: Purified by protein-A affinity chromatography

Concentration: 1 mg/ml

Storage Buffer: Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4

Storage / Stability: Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial

label.

Expiration: See vial label

Lot Number: See vial label

Background: CD229 (Ly9) is a cell surface receptor of the CD150 family, which includes also

e.g. CD48 and CD224. Receptors of this family regulate cytokine production and cytotoxicity of lymphocytes and NK cells. High levels of CD229 are found on T and B cells, where its expression increases during their maturation. It is absent on granulocytes, bone marrow-derived dendritic cells, platelets and erythrocytes. CD229 has been also reported on mouse monocytes and NK cells. CD229 interacts homophilically through its N-terminal domain and localizes to the contact site between T cells and antigen presenting B cells during antigen-dependent

immune synapse formation.



PRODUCT DATA SHEET

References:

*Del Valle JM, Engel P, Martín M: The cell surface expression of SAP-binding receptor CD229 is regulated via its interaction with clathrin-associated adaptor complex 2 (AP-2). J Biol Chem. 2003 May 9;278(19):17430-7.

*Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM: Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells. Exp Hematol. 2006 Jul;34(7):860-9.

*Romero X, Benítez D, March S, Vilella R, Miralpeix M, Engel P: Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue Antigens. 2004 Aug;64(2):132-44.

*Sintes J, Romero X, Marin P, Terhorst C, Engel P: Differential expression of CD150 (SLAM) family receptors by human hematopoietic stem and progenitor cells. Exp Hematol. 2008 Sep;36(9):1199-204.

*Martín M, Del Valle JM, Saborit I, Engel P: Identification of Grb2 as a novel binding partner of the signaling lymphocytic activation molecule-associated protein binding receptor CD229. J Immunol. 2005 May 15;174(10):5977-86.

*de la Fuente MA, Tovar V, Villamor N, Zapater N, Pizcueta P, Campo E, Bosch J, Engel P: Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. Blood. 2001 Jun 1;97(11):3513-20.

*Romero X, Zapater N, Calvo M, Kalko SG, de la Fuente MA, Tovar V, Ockeloen C, Pizcueta P, Engel P: CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse. J Immunol. 2005 Jun 1;174(11):7033-42.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.